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ABSTRACT
Objective: To estimate the incidence of severe
maternal sepsis due to group B Streptococcus (GBS)
in the UK, and to investigate the associated outcomes
for mother and infant.
Design: National case–control study.
Setting: All UK consultant-led maternity units.
Participants: 30 women with confirmed or suspected
severe GBS sepsis, and 757 control women.
Main outcome measures: Disease incidence,
additional maternal morbidity, critical care admission,
length of stay, infant infection, mortality.
Results: The incidences of confirmed and presumed
severe maternal GBS sepsis were 1.00 and 2.75 per
100 000 maternities, respectively, giving an overall
incidence of 3.75 per 100 000. Compared with
controls, severe GBS sepsis was associated with
higher odds of additional maternal morbidity (OR
12.35, 95% CI 3.96 to 35.0), requiring level 2 (OR
39.3, 95% CI 16.0 to 99.3) or level 3 (OR 182, 95%
CI 21.0 to 8701) care and longer hospital stay
(median stay in cases and controls was 7 days (range
3–29 days) and 2 days (range 0–16 days), respectively,
p<0.001). None of the women died. Severe maternal
GBS sepsis was associated with higher odds of infant
sepsis (OR 32.7, 95% CI 8.99 to 119.0); 79% of
infants, however, did not develop sepsis. There were
no associated stillbirths or neonatal deaths.
Conclusions: Severe maternal GBS sepsis is a rare
occurrence in the UK. It is associated with adverse
maternal and neonatal outcomes.
INTRODUCTION
Group B Streptococcus (GBS) or Streptococcus
agalactiae is a Gram-positive coccus found in
20% of healthy women as part of normal
gastrointestinal and genital tract ﬂora.1 2 It is
associated with pathogenicity in immuno-
compromised, elderly and pregnant adults as
well as infants and neonates.3 It is the
leading cause of culture-conﬁrmed neonatal
sepsis in the UK,4 accounting for over 50%
of culture-conﬁrmed cases that occur in the
ﬁrst 48 h after birth.5
Although sepsis-related maternal mortality
remains low in high-income countries and
has followed a steady decline over the past
century, its incidence has increased in the
UK where it is now one of the leading causes
of maternal death.6 While it is estimated that
2.1% of maternal deaths in high-income
countries result from maternal genital tract
sepsis,7 in the UK, sepsis-related maternal
deaths from all causes now represent almost
a quarter of all deaths.8 This increase has
been accompanied by a parallel rise in the
incidence and severity of sepsis in the
general population in Europe9 10 and the
USA,11 as well as an increase in maternal risk
factors for sepsis such as caesarean section
and obesity.12
Strengths and limitations of this study
▪ This study collected national data on presumed
or confirmed severe maternal group B
Streptococcus (GBS) sepsis over 12 months.
▪ The study was thus able to robustly estimate the
incidence of presumed and confirmed severe
maternal GBS sepsis, and the outcomes for
mothers and infants.
▪ The rarity of the condition severely limited the
power of this study to detect differences, and
thus the analyses of risk factors can only be
regarded as exploratory.
▪ The study included both confirmed and pre-
sumed cases of severe maternal GBS sepsis. It
is possible that some of the women with pre-
sumed GBS sepsis had other infecting organ-
isms and thus, may be regarded as false
positives.
▪ The study did not cross-check case identification
with laboratory sources; therefore, estimates of
incidence should be regarded as minimum
estimates.
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Although approximately 20% of women are GBS car-
riers,1 and GBS carriage is associated with early onset
GBS sepsis in neonates, only approximately 0.3% of
infants of carrier mothers develop sepsis, and 3 in
10 000 die.3 There is no clear association with other neo-
natal outcomes, such as preterm birth.13 Antenatal GBS
screening in pregnancy is thus not recommended by the
UK National Screening Committee. While much
research has focused on the risks and outcomes of neo-
natal GBS sepsis, there have been no comprehensive
studies documenting the incidence and epidemiological
characteristics of maternal GBS sepsis in the UK. Such
data are important for assessing the burden of disease
associated with GBS, and for providing guidance for the
clinical and cost-beneﬁt assessment of antenatal screen-
ing, treatment and vaccination.
The aim of this study was to use data from a larger
population-based study of maternal sepsis to estimate
the incidence of severe maternal sepsis due to presumed
or conﬁrmed GBS in the UK, and to investigate the asso-
ciated outcomes of severe maternal GBS sepsis for
mother and infant.
METHODS
Study design and setting
A national, population-based study was conducted
between June 2011 and May 2012 using the UK
Obstetric Surveillance System (UKOSS) to identify all
cases of severe maternal sepsis in the UK over a 1-year
period.14 This secondary analysis identiﬁed all cases of
severe GBS sepsis from the data set of women with
severe maternal sepsis from all causes.
Participants
Cases were all women in the UK identiﬁed as having
severe maternal GBS sepsis. Severe sepsis was deﬁned as
described in box 1. Severe maternal GBS sepsis was
deﬁned as any case of severe sepsis with laboratory con-
ﬁrmation of GBS (on blood, urine or vaginal swab cul-
tures). A ‘conﬁrmed’ severe GBS sepsis case was deﬁned
as GBS isolated from a sterile body site, such as blood,
and a ‘presumed’ case was deﬁned as severe sepsis
occurring in the context of positive GBS cultures from a
non-sterile site, such as urine or vaginal swab cultures,
where there was no other causal organism for the sepsis
clearly identiﬁed and where the clinical staff caring for
the women considered this to be the most likely cause of
her sepsis. ‘Presumed’ cases were included because
other studies of severe sepsis have indicated that a single
causative organism from sterile site culture cannot be
identiﬁed in almost 50% of cases.15
The control women were all controls identiﬁed in the
study of all-cause maternal sepsis.14 For the purposes of
this larger study, the controls were the two women who
did not have severe maternal sepsis and delivered imme-
diately before each case in the same hospital. Data from
all the control women in the data set were used for
comparison in this analysis in order to maximise the
study power; the controls used in this analysis are thus
not limited to the two women who did not have severe
maternal sepsis and delivered immediately before each
GBS case in the same hospital. Identical data were
collected about cases and controls except for details of
the sepsis itself.
Statistical methods
The incidence of severe maternal GBS sepsis was calcu-
lated using denominator data from national birth data
from 2011 as a proxy for June to December 2011 and
January to May 2012; the total number of maternities
(women delivering) during the 1-year study period was
estimated as 799 003.16–18
Baseline characteristics as well as maternal and infant
outcomes were compared in women with severe GBS
sepsis and controls by using the χ2 test for association,
Fisher’s exact test or the Wilcoxon rank-sum test, as
appropriate. Unconditional logistic regression analysis
was used to estimate ORs for binary outcomes and calcu-
late 95% CIs. Unconditional exact logistic regression was
used when appropriate. Unconditional logistic regres-
sion was also used in models comparing infant birth
weight in cases and controls adjusting for the a priori
confounder of gestational age at delivery. Models
looking at infant outcome included a speciﬁcation that
the calculated SEs allow for within group correlation in
order to allow for the non-independence of infants from
multiple pregnancies.19
Stata V.11 software was used for all statistical analyses.
For exposures of 20% prevalence in the controls, with
30 cases and 757 controls, the study had 65% power to
detect as statistically signiﬁcant an OR of 2.0 or greater;
for exposures of 2% prevalence, the power was only 9%.
Box 1 Definition of severe maternal sepsis
Any pregnant or recently pregnant woman (up to 6 weeks post-
partum) diagnosed with severe sepsis (irrespective of the source
of infection). Women were not reported if they were not consid-
ered by their attending obstetrician to have severe sepsis. As a
guide, a severe sepsis case would be expected to include women
in one of the following groups:
1. Death related to infection or suspected infection
2. Any women requiring level 2 or 3 critical care (or obstetric
high dependency unit type care) with severe sepsis or sus-
pected sepsis
3. Clinical diagnosis of sepsis in association with two or more of
the following:
A. Temperature >38°C or <36°C 4 h apart, on two
occasions
B. Heart rate >100 bpm persisting for over 4 h, on two
occasions
C. Respiratory rate >20/min for over 4 h or PaCO2
<32 mm Hg, on two occasions
D. White cell count >17 000 or <4000/mL or with >10%
immature band forms, on two occasions.
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This secondary analysis did not require Research
Ethics Committee approval. The original study was
approved by the London Research Ethics Committee
(ref 10/H0717/20).
RESULTS
All 214 hospitals in the UK with consultant-led maternity
units participated in the study (100%). Data collection
and case identiﬁcation are described in ﬁgure 1.
A total of 30 women with GBS-positive cultures in the
context of severe maternal sepsis were identiﬁed between
June 2011 and May 2012, including 1 woman with a twin
pregnancy. Of these, 7 were conﬁrmed cases of severe
maternal GBS sepsis and 23 were presumed cases of
severe maternal GBS sepsis. The different sources from
which GBS was isolated are listed in table 1.
The incidences of conﬁrmed and presumed severe
maternal GBS sepsis were 1.00 and 2.75 per 100 000
maternities, respectively, giving an overall incidence of
3.75 per 100 000 maternities.
Maternal characteristics are presented in table 2.
There were no statistically signiﬁcant differences
between cases and controls; however, the limited power
of this analysis must be noted.
Seventeen per cent (n=5) of the cases had been pre-
scribed antibiotics in the 2 weeks prior to delivery com-
pared with 4% of controls (OR 4.97, 95% CI 1.38 to 14.6,
p=0.015). Of the former, two had received antibiotics for
fever during labour, two had been treated for a urinary
tract infection (UTI) prior to delivery, and one had been
treated prophylactically after spontaneous rupture of
membranes given her past obstetric history of GBS in her
three previous pregnancies. No other women had been
given prophylactic antibiotics for GBS carriage.
There were no signiﬁcant differences in the propor-
tion of women who underwent invasive antenatal proce-
dures (such as amniocentesis, use of a urethral catheter,
Figure 1 Case reporting and
identification (GBS, group B
Streptococcus).
Table 1 Culture specimen collection sites
Culture specimen
collection site
Number of
specimens
Per
cent
Blood 7 23
Urine 3 10
High vaginal swab 11 36
Abdominal wound 2 7
Placental swab 5 17
Low vaginal swab 2 7
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intravenous or intra-arterial lines) among cases and con-
trols (data not shown), but again the limited power of
this analysis must be noted.
Diagnosis of severe sepsis
Two women had a miscarriage; both women were diag-
nosed with presumed severe GBS sepsis prior to their
miscarriage. The 28 remaining women had live births.
Thirteen had an antenatal and 15 a postnatal diagnosis
of severe GBS sepsis.
Among the 13 antenatal cases of severe sepsis in
women with ongoing pregnancies, the median time
between the diagnosis of sepsis and delivery was 1 h
46 min (range 1 h 3 min–36 days). Only two cases of
severe antenatal sepsis were diagnosed before mem-
brane rupture; both had clear risk factors for severe
sepsis, including one case with a GBS-positive UTI and
reported subsequent chorioamnionitis, and the second
with pyelonephritis. Nine out of the 13 antenatal cases
laboured; 7 were diagnosed with severe sepsis after the
onset of labour and 2 were diagnosed with severe sepsis
before the onset of labour. The four women who did
not go into labour were delivered by caesarean section.
For the 15 cases of postnatal sepsis, the median time
between delivery and diagnosis of severe sepsis was 41 h
45 min (range 2 h 45 min–14 days); the median time
between rupture of membranes and diagnosis of severe
sepsis was 2 days 13 h (range 19 h–15 days). Only one
case of severe postnatal sepsis did not go into labour
(delivered by caesarean section in the presence of rup-
tured membranes).
Maternal delivery and outcomes
The mode of delivery for control women and the 28
women with ongoing pregnancies is described in table 3.
All women delivered by caesarean section were given
prophylactic antibiotics. Antenatal severe GBS sepsis was
associated with raised odds of delivery by caesarean
section (OR 14.1, 95% CI 3.04 to 131.9). In the 11 cases of
caesarean section in the context of antenatal severe mater-
nal GBS sepsis, indications for caesarean section included
maternal compromise due to sepsis (n=9), fetal tachycar-
dia (n=4) and failure to progress in labour (n=4).
Table 2 Maternal characteristics
Number (%)* of cases Number (%)* of controls OR (95% CI)
n=30 n=757
Maternal factors
Maternal age (years)
<35 24 (80) 596 (79) 1
35+ 6 (20) 160 (21) 1.09 (0.46 to 2.57)
Ethnic group
White 21 (70) 598 (79) 1
Non-white 9 (30) 156 (21) 1.83 (0.84 to 3.96)
Socioeconomic status
Managerial 8 (27) 189 (26) 1
Other employed/unemployed 22 (73) 548 (74) 0.99 (0.44 to 2.25)
Marital status
Married/cohabiting 25 (83) 630 (84) 1
Single 5 (17) 124 (16) 0.98 (0.37 to 2.59)
Smoking status during pregnancy
Did not smoke 26 (87) 581 (77) 1
Smoked 4 (13) 173 (23) 0.52 (0.18 to 1.50)
Parity
0 12 (40) 330 (44) 1
1+ 18 (60) 427 (56) 1.16 (0.55 to 2.44)
Body mass index
Normal or overweight (<30) 18 (64) 564 (77) 1
Obese (≥30) 10 (36) 170 (23) 1.84 (0.83 to 4.07)
Multiple pregnancy
Yes 1 (3) 8 (1) 1
No 29 (97) 746 (99) 3.21 (0.07 to 25.31)
Pre-existing medical conditions
Yes 11 (37) 242 (32) 1.22 (0.57 to 2.60)
No 19 (63) 510 (68) 1
Previous pregnancy complications
Yes 8 (27) 148 (20) 1.49 (0.65 to 3.42)
No 22 (73) 607 (80) 1
*Percentage of individuals with complete data.
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Postnatal severe GBS sepsis was associated with raised odds
of instrumental vaginal delivery (OR 4.40, 95% CI 1.26 to
14.2), and decreased odds of normal vaginal delivery (OR
0.17, 95% CI 0.03 to 0.66). In the six cases of caesarean
section in the context of postnatal severe maternal GBS
sepsis, indications for caesarean section included breech
presentation (n=2), chorioamnionitis (n=1), pre-eclampsia
and prolonged preterm rupture of membranes (n=1), and
failure to progress in labour (n=3).
There was no statistically signiﬁcant difference in the
number of vaginal examinations between cases and con-
trols; the median number of examinations in both cases
and controls was 3 (ranges 1–12 and 0–10, respectively).
Twenty-three per cent of women with severe GBS sepsis
(n=7) had additional major maternal morbidity (OR
12.4, 95% CI 3.96 to 35.0, p≤0.001). These included pul-
monary oedema (n=1), coagulopathy (n=1), postpartum
haemorrhage (n=3), retroperitoneal haematoma/pseu-
doaneurysm (n=1), thrombocytopaenia (n=1), bilateral
iliopsoas abscesses (n=1) and necrotising fasciitis (n=1).
No women died in either group.
Women with severe maternal GBS sepsis had signiﬁ-
cantly higher odds of receiving intensive care compared
with controls, as well as a signiﬁcantly longer length of
hospital stay following delivery (table 4). The median
length of stay in hospital after diagnosis of severe sepsis
was 6 days (range 2–39 days). Five women with severe
GBS sepsis had no signs of infection during their initial
hospital admission and were discharged home before
being admitted with a diagnosis of severe sepsis.
Infant outcomes
There were 29 live births to 28 women with severe GBS
sepsis and no stillbirths or neonatal deaths. Cases were
more likely to deliver preterm with 31% (OR 6.00, 95%
CI 2.45 to 14.7) and 14% (OR 13.4, 95% CI 3.11 to
57.3) of infants being born before 37 and 32 completed
weeks, respectively (table 5). Of the 9 infants born
preterm, 4 (44%) were iatrogenic preterm deliveries (3
of 4 deliveries before 32 weeks).
The odds of the infant developing sepsis were also sig-
niﬁcantly higher in severe maternal GBS sepsis cases
(OR 32.7, 95% CI 8.99 to 119.0, p<0.001); 21% of
infants of mothers with severe GBS sepsis developed
sepsis. Information on the causative organisms of infant
sepsis was not available. All four infants of cases who
were born ‘very preterm’ (<32 weeks gestation) were
born to women with antenatal sepsis; three were deliv-
ered electively by prelabour caesarean section, two in
the presence of ruptured membranes and one in the
presence of intact membranes, and one was delivered
spontaneously vaginally.
DISCUSSION
Main findings
This study suggests that severe maternal GBS sepsis is
rare in the UK, with an incidence of conﬁrmed severe
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maternal GBS sepsis of 1 case per 100 000 maternities.
Severe maternal GBS sepsis was associated with add-
itional maternal morbidity, longer hospital stays and
increased odds of maternal readmission compared with
controls. It was also associated with increased odds of
infant sepsis and a longer infant stay in neonatal special
care units. There were no maternal or neonatal deaths
or stillbirths associated with severe maternal GBS sepsis
during the course of the study; however, given the small
number of cases, this should be interpreted with
caution.
Strengths and limitations
Despite having collected national data over 12 months,
the rarity of the condition severely limited the power of
this study to detect differences and thus, it can only be
regarded as exploratory. It is possible that real differ-
ences in maternal characteristics, such as non-white eth-
nicity, obesity and multiple pregnancy, have been subject
to type II error and we were unable to identify these as
statistically signiﬁcantly associated with maternal severe
GBS sepsis. Thus, although real differences might exist,
we did not identify any statistically signiﬁcant risk factors.
We included both conﬁrmed and presumed cases of
severe maternal GBS sepsis since in the previous studies
almost 50% of cases of severe sepsis had no deﬁnitive
causal organism identiﬁed from sterile site culture.15 UK
national guidelines recommend that blood cultures are
performed in all women meeting our deﬁnition of
severe sepsis,20 21 but from these data we do not know in
what proportion of women this was undertaken. It is pos-
sible that some of the women with presumed severe GBS
sepsis had other infecting organisms and may be
regarded as false positives. UKOSS is only able to collect
anonymous information; we were thus not able to cross-
check case ascertainment with national laboratory or
other data, which may have identiﬁed additional cases.
However, cross-checking with national data on maternal
deaths showed that there were no maternal deaths from
GBS sepsis during this period;8 it is thus reassuring that
this study did not fail to identify any maternal deaths.
Owing to our inability to cross-check cases with labora-
tory sources, our estimates of incidence should be
regarded as minimum estimates.
Interpretation
Our study found the incidence of severe maternal GBS
sepsis to be substantially lower than that reported by a
population surveillance study (1999–2005) in the USA
(12 per 100 000, yearly range 11–14 per 100 000 live
births)22 that had analysed all cases of conﬁrmed inva-
sive maternal GBS disease (with positive culture from a
sterile body site). In this US study, 61% of women with
invasive GBS disease had a miscarriage or stillborn
infant, 30% had infants without apparent illness, 5%
had live-born infants who developed clinical infections
and 4% had termination of pregnancy. Similarly, a
Canadian population-based surveillance study in 1996
investigating positive laboratory cultures of GBS from
sterile body sites found the incidence of maternal GBS
infection to be 41 per 100 000 total births, with only
73% of maternities resulting in the delivery of a live
infant;23 interestingly, no live births were found to be
infected with GBS. The estimate of incidence of severe
maternal sepsis identiﬁed in the main study14 was com-
patible with estimates from other countries, suggesting
that there was not signiﬁcant under-reporting of cases.
The difference in the incidence of severe GBS sepsis
found in the present study could be explained by the
fact that only cases which met the criteria for severe
sepsis were included in our case deﬁnition; however, in
the light of our inability to cross-check data with
Table 4 Maternal outcomes in cases and controls
Number (%)* of cases Number (%)* of controls
OR (95% CI)n=30 n=757
Maternal outcome
Readmission after delivery*
Yes 7 (23) 17 (2) 13.12 (4.16 to 37.56)
No 23 (77) 740 (98) 1
Level 2 care
Yes 17 (57) 24 (3) 39.25 (15.99 to 99.31)
No 13 (43) 733 (97) 1
Level 3 care
Yes 6 (20) 1 (0) 182 (20.98 to 8701.16)
No 24 (80) 756 (100) 1
Major maternal morbidity
Yes 7 (23) 18 (2) 12.35 (3.96 to 35.01)
No 23 (77) 737 (98) 1
Length of hospital stay following delivery;
median (range) (days)
7 (3–29) 2 (0–16) p<0.001
*Percentage of individuals with complete data.
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l- aboratory sources, we cannot exclude the possibility of
underascertainment. As our case deﬁnition was of
‘severe sepsis’, less severe forms of invasive maternal
GBS disease would not have been included in our ana-
lysis. This is in contrast to other studies, including those
noted above, which have measured the incidence of
maternal GBS disease where the only inclusion criterion
has been the presence of laboratory evidence of GBS
from a sterile maternal body site, irrespective of the
woman’s clinical condition. Women included in these
other studies may have an infection, but not necessarily
severe sepsis. The difference in incidence observed
between these studies using only laboratory sources and
our study using clinical sources may, therefore, partly be
explained by the fact that some cases of maternal GBS
disease do not meet our deﬁnition of severe maternal
sepsis. Our study also found infant morbidity and mor-
tality associated with severe maternal GBS sepsis to be
lower than other studies. A possible explanation could
be the lack of correlation between severity of maternal
and infant GBS disease. It is important to note, however,
that 21% of infants of mothers with severe GBS sepsis
developed sepsis; the raised odds of infant infection we
observed is in line with that associated with maternal
GBS carriage in other studies.24
It is, however, important to note that vaginal colonisa-
tion by GBS occurs in up to 20% of the population.
Thus, some of the cases of severe sepsis which we found
to have occurred in the presence of GBS-positive labora-
tory cultures that are not from sterile sites may have
been caused by other pathogens with GBS being a col-
oniser and thus, these represent false-positive cases. This
may partly account for the apparently better infant out-
comes than in other studies.
These data help to inform the ongoing debate about
antenatal GBS screening by providing information
about the maternal burden of severe GBS sepsis in the
UK. The data from this study, including the associated
hospital and intensive care unit stay data and asso-
ciated costs for both mothers and infants after diagno-
sis of sepsis, could contribute to a cost-effectiveness
study of antenatal screening for GBS. Antenatal
screening, which is now common practice in the USA
and several European countries, aims to identify
maternal GBS colonisation at 36–38 weeks gestation,
through vaginal-rectal swabs, for management with
intrapartum antibiotic prophylaxis (IAP). The UK is
currently using a risk factor-based approach where IAP
is only administered to women with antenatal or intra-
partum risk factors for sepsis. Review of the latest avail-
able evidence has identiﬁed major limitations of
antenatal GBS culture screening whereby the positive
and negative predictive values of the test were found
to be 50.5% and 91.7%, respectively.4 Real time PCR
at the time of labour appears to be a more accurate
way of testing colonisation at the time of labour, but
evidence from studies assessing the validity of this
method is still lacking.4 It is also important to note, as
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part of the assessment of the risks and beneﬁts of
screening and prophylaxis, that intrapartum prophy-
laxis with penicillin may have additional beneﬁts for
the mother in terms of protection against other inva-
sive organisms, such as group A Streptococcus, an
important cause of severe maternal sepsis identiﬁed in
the original study.14
Vaccination of pregnant mothers against GBS provides
another avenue for the prevention of maternal and neo-
natal GBS disease. Both laboratory research and early
phase randomised controlled trials are currently
ongoing investigating the immunogenicity and safety of
potential GBS vaccines in pregnant women.4
CONCLUSIONS
Conﬁrmed severe maternal GBS sepsis appears to be
rare, and these data can be taken into account when
considering the risks and beneﬁts of population screen-
ing and immunisation programmes. The rarity of the
condition severely limits the power of this analysis to
identify potential risk factors. A multinational study,
such as through the International Network of Obstetric
Survey Systems (INOSS),25 would be required to identify
a larger numbers of cases for a robust investigation of
associated factors. This study also raises questions con-
cerning the association between the severity of maternal
and infant disease that would also beneﬁt from further
investigation in a larger study.
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